Project description
Insulin signalling underlies the morbidity of illnesses
Insulin signalling deregulation is implicated in diabetes, metabolic syndrome and obesity. Insulin's multimorbidity role extends to the brain, where altered insulin signalling is associated with dementia as seen in Alzheimer's disease and mental conditions characterised by compulsive behaviour such as obsessive compulsive disorder and autism. The EU-funded PRIME project brings together a multidisciplinary team to develop the novel concept of insulin signalling as a key factor in the multiple forms of morbidity associated with major mental and somatic illnesses. Their research will help to understand insulin multimorbidity across the lifespan, uncovering the mechanisms linking somatic and mental insulin-related illnesses. The project will also develop tools for early diagnosis, clinical care and prevention of insulin-related morbidity conditions.
Objective
PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is still largely underestimated, since insulin multimorbidity also extends to the brain, where altered insulin signalling appears to be implicated in dementias such as Alzheimer disease and – based on our pilot work - in mental illnesses characterized by compulsivity, especially obsessive compulsive disorder and autism. We therefore further posit that insulin multimorbidity evolves throughout life, necessitating a lifespan approach.
PRIME brings together a multidisciplinary team to (1) extend our understanding of insulin multimorbidity across the lifespan, (2) understand the causal mechanisms linking somatic and mental insulin-related illnesses, (3) develop tools for early diagnosis, improved clinical care, and prevention of insulin-related lifespan multimorbidity. We will leverage the world’s largest registry, clinical cohort, and population data sets to identify and validate new insulinopathies. Through an interdisciplinary battery of innovative approaches, we will clarify the causal mechanisms linking peripheral and central insulin signalling to body-brain comorbidity, integrating across animal models and studies in humans from molecule to cell, brain, cognition, and behaviour. Our prior evidence enables PRIME to bring the new knowledge to society, based on e.g. repurposing medication and lifestyle interventions (diet/exercise monitored by mHealth assessment), identifying and validating novel drug targets, developing and testing candidate biomarkers, and by improving existing medical guidelines and policy. Furthermore, educational approaches to inform clinicians, patients, and general public will be developed.
Fields of science
- medical and health sciencesclinical medicinepsychiatryobsessive-compulsive disorder
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health scienceshealth sciencesnutritionobesity
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (22)
6525 EC Nijmegen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35000 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35000 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
35042 Rennes
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
43003 Tarragona
See on map
68159 Mannheim
See on map
8000 Aarhus C
See on map
69120 Heidelberg
See on map
60323 Frankfurt Am Main
See on map
00161 Roma
See on map
6200 MD Maastricht
See on map
3584 BK Utrecht
See on map
1000 Bruxelles / Brussel
See on map
82256 Furstenfeldbruck
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1085 Budapest
See on map
5020 Bergen
See on map
1181 VX Amstelveen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08007 Barcelona
See on map
Participation ended
6525 XZ Nijmegen
See on map